Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $165.00 -5.17%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of $1.99, $1.08 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.12 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.56 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- This Swiss stock is ‘well positioned to deliver’ profitable growth: Citi
- Oxford Square Capital Corp. (OXSQ) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
